Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.
Maréchal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman TC, Hervé C, Rheault P, Talli J, Wauters D, Oostvogels L. Maréchal C, et al. Among authors: herve c. Vaccine. 2018 Jul 5;36(29):4278-4286. doi: 10.1016/j.vaccine.2018.05.110. Epub 2018 Jun 11. Vaccine. 2018. PMID: 29903674 Free article. Clinical Trial.
Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial' [Vaccine 36 (2018) 4278-4286].
Maréchal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman TC, Hervé C, Rheault P, Talli J, Wauters D, Oostvogels L. Maréchal C, et al. Among authors: herve c. Vaccine. 2019 Feb 21;37(9):1252-1253. doi: 10.1016/j.vaccine.2019.01.022. Epub 2019 Jan 30. Vaccine. 2019. PMID: 30711316 Free article. No abstract available.
Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.
Oostvogels L, Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P, Zahaf T, Dagnew AF, Chlibek R, Diez-Domingo J, Gorfinkel IS, Hervé C, Hwang SJ, Ikematsu H, Kalema G, Lal H, McNeil SA, Mrkvan T, Pauksens K, Smetana J, Watanabe D, Weckx LY, Cunningham AL. Oostvogels L, et al. Among authors: herve c. Hum Vaccin Immunother. 2019;15(12):2865-2872. doi: 10.1080/21645515.2019.1627818. Epub 2019 Jun 28. Hum Vaccin Immunother. 2019. PMID: 31216205 Free PMC article. Clinical Trial.
Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials.
Colindres R, Wascotte V, Brecx A, Clarke C, Hervé C, Kim JH, Levin MJ, Oostvogels L, Zahaf T, Schuind A, Cunningham AL. Colindres R, et al. Among authors: herve c. Hum Vaccin Immunother. 2020 Nov 1;16(11):2628-2633. doi: 10.1080/21645515.2020.1741312. Epub 2020 Apr 29. Hum Vaccin Immunother. 2020. PMID: 32347767 Free PMC article.
Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.
Schmader KE, Levin MJ, Chen M, Matthews S, Riley ME, Woo W, Hervé C, Grupping K, Schuind AE, Oostvogels L, Curran D. Schmader KE, et al. Among authors: herve c. J Gerontol A Biol Sci Med Sci. 2021 Feb 25;76(3):485-490. doi: 10.1093/gerona/glaa127. J Gerontol A Biol Sci Med Sci. 2021. PMID: 32530462 Free PMC article. Clinical Trial.
Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients.
Ocran-Appiah J, Boutry C, Hervé C, Soni J, Schuind A; ZOSTER-056 Study Group. Ocran-Appiah J, et al. Among authors: herve c. Vaccine. 2021 Jan 3;39(1):6-10. doi: 10.1016/j.vaccine.2020.10.029. Epub 2020 Dec 1. Vaccine. 2021. PMID: 33277059 Free article. Clinical Trial.
484 results